Cooper Companies' Q2 2026 Performance and Strategic Developments

Cooper Companies Reports Record Q2 2026 Revenue Amid Strategic Developments

In its fiscal second quarter ending April 30, 2026, Cooper Companies (NASDAQ: COO) achieved a record revenue of $1.082 billion, marking an 8% increase from the previous year. This growth was driven by strong performances in both the CooperVision and CooperSurgical segments. Non-GAAP diluted earnings per share (EPS) rose by 26% to $1.21, surpassing analyst expectations of $1.10. However, the company reported a GAAP diluted EPS of $(0.40), primarily due to a $271.6 million litigation-related charge associated with a December 2023 product recall at CooperSurgical.

Strategic Review and Potential Divestiture

Cooper Companies is actively exploring strategic alternatives for its CooperSurgical division. The company has received significant interest from multiple parties regarding this segment. Analysts, including those from Stifel, view this development as a positive step toward potentially transforming Cooper into a pure-play contact lens company under CooperVision.

Analyst Perspectives and Stock Performance

Following the Q2 earnings report, several analysts adjusted their outlooks on Cooper Companies. Needham lowered its price target to $86 from $101, citing a softer outlook for the latter half of fiscal 2026, particularly in the Asia-Pacific region. Piper Sandler also reduced its price target to $86 from $94, expressing concerns about potential revenue and growth shortfalls. Despite these adjustments, the stock experienced a surge of over 8% following the earnings announcement, reflecting investor optimism about the company’s performance and strategic direction.

Financial Highlights

As of July 11, 2026, Cooper Companies’ stock is trading at $70.70, with a market capitalization of approximately $13.79 billion. The company maintains a price-to-earnings (P/E) ratio of 55.23, based on an EPS of $1.28. The stock’s 52-week range spans from $58.89 to $89.83, indicating significant volatility over the past year.

Conclusion

Cooper Companies’ record revenue in Q2 2026 and the strategic review of its CooperSurgical division highlight the company’s proactive approach to growth and portfolio optimization. While litigation-related charges have impacted GAAP earnings, the company’s strong operational performance and potential divestiture plans have garnered positive attention from investors. Stakeholders will be closely monitoring the outcomes of the strategic review and subsequent financial performance in the coming quarters.